Impact of Baseline BCVA on Outcomes with Aflibercept 8 mg in Patients with DME

Key Points

• To assess how baseline best-corrected visual acuity (BCVA) influences treatment outcomes with aflibercept in diabetic macular edema (DME).
• Comparison of aflibercept 8 mg to 2 mg in DME patients.
• Evaluation of visual and anatomic improvements at week 96.
• Analysis based on baseline BCVA categories: ≤20/50 and ≥20/40.
• Both dosages showed comparable visual improvements at week 96.
• Anatomic improvements were similar across different baseline BCVA groups.